Apple Card Savings Account has taken another hit to its interest rate as of today. Apple and Goldman Sachs have dropped the annual percentage yield from 3.75% to 3.65%, marking the second rate cut ...

Apple Wants To Get Into Your Head, Literally. getty In the book, “ Infinite Education,” I wrote about the advancing front of brain-computer interfaces. When exploring these artificial ...

Apple shares tend to perform better when stock-buyback activity is below average By Mark Hulbert Last Updated: May 7, 2025, 3:19 p.m. ET First Published: May 7, 2025, 9:32 a.m. ET Share ...

Piling into this classic pharma play While TRS cut a number of its top positions, it also increased its stake in the pharmaceutical giant Eli Lilly(NYSE: LLY) by 11% in the quarter.

Like other streamers, over time, Apple TV+ has made changes to help generate more revenue, cut costs and increase customers. Last month, Apple cut the price of its streaming service temporarily to ...

Apple shares dropped 5% on Friday after the company reduced its stock buyback program by $10 billion and CEO Tim Cook revealed a $900 million hit to costs this quarter due to escalating US-China ...

Finally, LSV Asset Management bought a new position in shares of Apple in the 4th quarter worth approximately $65,000. 67.73% of the stock is currently owned by institutional investors.

During Wednesday’s earnings call, Apple CEO Tim Cook went into the most detail yet on how the company is responding to the far-reaching US tariffs imposed by President Trump — and the ...

Today, second-quarter 2025 earnings are out and Apple reported record revenue of $95.4 billion, a 5% year-over-year gain. The diluted earnings per share was $1.65 an 8% year-over-year gain. Tim Cook ...

UPDATE: Tim Cook on tariff impact: Apple chief executive Tim Cook said the company anticipates $900 million in additional costs for the current June quarter amid Donald Trump ’s tariffs ...

And one aspect of Apple’s report that stood out: China was the only market where sales declined year-over-year; revenue from China dropped 2.25% to $16.00 billion for the quarter.

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.